Abstract
Introduction

Naive CD4
+ Th cells recognize an antigenic peptide through their TCR in the context of MHC class II molecules on antigenpresenting cells (APC) and undergo differentiation to effector cells that can produce cytokines and chemokines. During this process, naive CD4 + T cells can differentiate to at least two functionally distinct subsets of cells, represented by Th1 and Th2 (1) . Th1 cells produce IFN-c and lymphotoxin (TNF-b) in addition to IL-2 and are responsible for directing cell-mediated immune responses leading to the eradication of intracellular pathogens such as Mycobacterium, viruses and parasites (1) (2) (3) (4) . Th1 cells also regulate IgG2a and IgG3 antibody production via IFN-c production, which is involved in the opsonization and phagocytosis of particulate microbes. Th2 cells secrete IL-4, IL-5 and IL-13 as effector cytokines and are responsible for humoral immune responses for the eradication of helminths. Th2 cells also cause inflammatory damage during allergic diseases, such as asthma and atopic dermatitis. The process by which an uncommitted Th cell develops into a mature Th1 or Th2 subset is a matter of fact for regulating the immune response to various antigens.
Considerable progress has been made in identifying the factors that govern the progression of cell differentiation during the generation of Th subsets (2) (3) (4) . Using T cells stimulated with polyclonal activators or T cells from mice expressing transgenic antigen receptors of known specificities, it has become clear that Th1 and Th2 subsets develop from the same T cell precursor (5-7), which is a naive CD4 + T cell. There is a body of evidence to indicate that the cytokines IL-12 and IL-4 are key determinants of the Th1 and Th2 response, respectively (4) . For example, IL-12 directs Th1 development from antigen-stimulated naive CD4 + T cells and activates STAT4 in Th1 cells (8, 9) . In terminally differentiated Th1 cells, successive IFN-c production can occur through TCR ligation or IL-12 and IL-18 stimulation. Using mice deficient in either cytokines or STAT, it has been shown that activation of the IFN-cR/STAT1 is also important for the differentiation of CD4 + T cells into Th1 cells (10, 11) . The IL-4R/STAT6 signaling pathway plays a central role in the differentiation of naive CD4 + T cells into Th2 cells (12) (13) (14) . The balance of IFN-c and IL-4 levels present during T cell activation is considered to be the major influence on Th1 versus Th2 differentiation. Although the strength of the interaction mediated through TCR and MHC/ peptide complex is suspected to affect the lineage commitment of Th cells to Th1 cells and clonal expansion (15) (16) (17) , it remains unclear whether Th1 cells can develop from naive CD4 + T cells upon antigenic peptide stimulation in the presence of APC under neutral conditions. Ag85B (also known as a antigen or MPT59) is the most potent antigen species yet purified for both humans and mice (18) . Ag85B can elicit strong Th1 response in vitro from PPD + asymptomatic individuals (19) (20) (21) . We have shown that in vitro stimulation of lymph node cells from Mycobacterium tuberculosis-primed C57BL/6 mice with Ag85B induces the production of IFN-c and IL-2 and expansion of CD4 + T cells expressing Vb11 of TCR (TCRVb11) in an I-A b -restricted manner (22, 23) . We identified the 15-mer peptide (Peptide-25), covering amino acids residues 240-254 (FQDAYNAAGGHNAVF) of Ag85B, as the major epitope for Ag85B-specific TCRVb11 + T cells (22) . Using Peptide-25-reactive Vb11 + Tcell clones (BP1, BP4, BM5, BM7 and BM12) and substituted Peptide-25 mutants, we determined which amino acid residues within Peptide-25 were critical for TCR recognition (23, 24) . Peptide-25 contains the motif that is conserved for I-A b binding and requires processing by APC to trigger Ag85B-specific TCRVb11 + T cells (22) . Active immunization of C57BL/6 mice with Peptide-25 can induce the differentiation of CD4 + TCR Vb11 + Th1 that produce IFN-c and TNF-a and protect against subsequent infection with live M. tuberculosis H37Rv (23).
Here we generate transgenic mice (P25 TCR-Tg) expressing functional TCR that interacts with Peptide-25 in conjunction with I-A b . We report that naive CD4 + T cells in the spleen of P25 TCR-Tg mice respond specifically to Peptide-25 in the presence of APC from I-A b mice and differentiate to Th1 cells in the absence of IFN-c or IL-12 under neutral conditions.
Methods
Mice
C57BL/6 mice were purchased from Japan SLC Inc. (Hamamatsu, Japan). STAT1 deficient mice were kindly provided by Dr R. D. Schreiber, Center for Immunology, Washington University School of Medicine. These mice were maintained under specific pathogen-free conditions in our animal facility according to our Institute's guidelines, and used at 8-15 weeks of age.
Cell lines
Five different Peptide-25-reactive CD4 + Th1 clones (BP1, BP4, BM5, BM7 and BM12) were established in vitro by culturing lymph node cells from C57BL/6 mice immunized with heatkilled M. tuberculosis H37Rv as described (23) . TG40 is a variant T cell hybridoma cell line lacking the expression of surface TCR-a and -b chains that has been used a recipient cells for TCR (25) . PLAT-E is a packaging cell line that produces retroviruses (26) . Chinese hamster ovary cells expressing I-A b (I-A b -CHO) (27) were kindly provided by Dr Y. Fukui (Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan).
Reagents and antibodies
All peptides including Peptide-25 and its substituted mutants were synthesized by Funakoshi Co. Ltd (Tokyo, Japan). Anti-IFN-c-FITC (XMG1.2), anti-IL-4-allophycocyaninn (11B11), anti-Vb11-PE (RR3-15), anti-CD4-FITC or -PE (GK1.5), anti-CD8-PE (53.6.72), anti-CD25-FITC (7D4), anti-CD28-FITC (37.51), anti-CD69-FITC (H1.2F3), anti-CD44-FITC (IM7), anti-CD45RB-PE (16A) and anti-LFA1-FITC (2D7) were purchased from BD Biosciences PharMingen (San Diego, CA). Purified anti-CD3 e (2C11), anti-IFN-c (R4-6A2) and anti-IL-12 (C17.8) were purchased from BD Biosciences PharMingen.
Subcloning of TCR
Total cellular RNA was isolated from BP1 by using acid guanidinium-phenol-chloroform method. cDNA was synthesized with random hexamer primers and superscript II cDNA kit (GIBCO BRL, Grand Island, NY). 59-Rapid amplification of cDNA end (59-RACE) was performed using the 59-RACE System Ver.2.0 (Life Technologies, Rockville, MD) according to the manufacturer's instructions. The first strand of cDNA was synthesized with gene-specific primer 1 (59-ATCCATAGCTTT-CATGTCCA for TCR a-chain and 59-GCCATTCACCCAC-CAGCTCA for TCR b-chain). The first PCR amplification was carried out by using gene-specific primer 2 (59-GCGAATTCT-GAGACCGAGGATCTTTTAACTGGTAC for TCR a-chain and 59-GCGTCGACTCTGCTTTTGATGGCTCAAAC for TCR bchain). The second PCR amplification was carried out with nested gene-specific primer (59-GCGTCGACACAGCAGG-TTCTGGGTTCTGGAT for TCR a-chain and 59-GCGTCGA-CAAGGAGACCTTGGGTGGAGTCAC for TCR b-chain). The PCR fragment was subcloned in Bluescript SK + and sequences by automatic DNA sequencer (ABI PRISM 3700 DNA analyzer, Applied Biosystems, Foster City, CA).
Retrovirus-mediated gene transfer
Full length cDNAs genes encoding the TCR a-and b-chains of BP1 were inserted into a retroviral vector pMX-IRES-GFP vector, pMX-BP1-a and pMX-BP1-b, respectively, and were transfected into a retroviral packaging cell line, PLAT-E with LipofectAMINE Plus Reagent (GIBCO BRL) (28) The cultured supernatant of PLAT-E after 24 h culture was collected, and added to TG40 cells together with DOTAP Liposomal Transfection Reagent (Roche Diagnostics GmbH, Mannheim, Germany) (29) . Transfection was monitored by the cell surface expression of TCR by FACS analysis. TG40 cells were transfected with each of plasmids or in their combinations and selected TG40 cells expressing TCR-ab (TG40-BP1). TG40-BP1 cell line for expression of CD4 (TG40-BP1/CD4) was established by electroporation of the expressible constructs of full length CD4 cDNA into TG40-BP1 cells by Gene Pulser (Bio-Rad laboratories, Hercules, CA).
Establishment of transgenic mice
The transgenic TCR-a and -b genes were isolated from BP-1 as described in the previous session. The DNA sequences of the PCR products revealed that BP1-TCR-a was composed of Va5, Ja15 and Ca1, and the TCR-b chain of Vb11, Jb2.3 and Cb2. The pHSE39 plasmid contains the H-2K b promoter (provided by H. Pircher), a poly(A) signal from b-globin and the immunoglobulin heavy chain enhancer (30) . The full-length BP1 TCR a and b cDNAs were subcloned into the SalI and BamHI sites of the expression vector pHSE39 plasmid under control of the H-2K b promoter. The constructs were excised from these plasmids by XhoI cleavage for TCR-a chain and ApaLI cleavage for TCR-b, and purified by using QIAEX II gel extraction system (Qiagen Inc., Valencia, CA). The purified expression constructs for TCR a and b cDNAs were coinjected into fertilized eggs of C57BL/6 mice. We finally obtained a TCR-Tg line of mice expressing TCR-Va5-Vb11 (P25 TCR-Tg). P25 TCR-Tg mice were bred to STAT1 deficient mice (STAT1 deficient P25 TCR-Tg) on a C57BL/6 background in our animal faculty under specific pathogen-free conditions.
Preparation of naive CD4
+ T cells and APC Splenic T cells from either P25 TCR-Tg or littermate C57BL/6 mice were enriched by passing splenocytes through a nylon wool column. To further purify primary CD4 + T cells, the splenic T cells were incubated with a mixture of Microbead-bound monoclonal antibodies that were specific for CD8 (53-6. To examine Th differentiation in vitro, two-step cultures were employed. For the first culture, purified splenic naive CD4 + T cells (5 3 10 5 /culture) were activated for 6 days with 10 lg/ml of anti-CD3 or 10 lg/ml Peptide-25 or its substituted mutant in the presence of T-and NK cell-depleted C57BL/6 splenic APC (2.5 3 10 6 /culture) in a 48-well plate. In some experiments, we used Peptide-25 loaded I-A b -CHO (2.5 3 10 5 /culture) as APC. For the second culture, the cells collected from the first culture were extensively washed and dead cells were removed by centrifugation through Ficol-Hypaque gradients. The viable primed CD4 + T cells were re-stimulated with 10 lg/ml of anti-CD3 or 10 lg/ml of Peptide-25 in the presence of splenic APC or 1 lg/well of immobilized anti-CD3.
Intracellular cytokine staining and FACS analysis
We identified cytokine-producing cells by cytoplasmic staining with anti-cytokine antibody as previously described (24) . First, 2 lM of Monensin (BD Biosciences PharMingen) was added to the secondary culture for the last 4 h of each stimulation. The cells were harvested at 24 h of the secondary culture and stained with 7-amino-actinomycin D and with anti-Vb11-PE or anti-CD4-PE. The cells were fixed with 4% formaldehyde after washing with 0.05% azide-1% FCS-PBS, permeabilized with 0.1% saponin, and stained with both anti-IFN-c-FITC and anti-IL-4-allophycocyanin. Isotype-matched control antibodies were also used. The cells stained were gated on live Vb11-or CD4-positive cells and analyzed on a FACSCalibur instrument (Becton Dickinson, Mountain View, CA).
ELISA
Amounts of IL-2, IL-4 and IFN-c in the culture supernatant were measured by ELISA. All monoclonal antibodies specific for mouse IL-2, IL-4 and IFN-c used for capture and detection of cytokines were purchased from BD Biosciences PharMingen. ELISA was performed following the instruction of BD Biosciences PharMingen.
ELISPOT assay
Cytokine producing cells were identified by ELISPOT assay, using the IFN-c and IL-4 ELISPOT assay kits (R&D Systems, Minneapolis, MN). After naive CD4 + T cells from P25 TCR-Tg mice were cultured with Peptide-25-loaded I-A b -CHO for 20 h in a 96-well plate coated with capture antibodies, ELISPOT assay was performed following the manufacturer's instructions. Spots were analyzed by KS ELISPOT compact (Carl Zeiss, Oberkochen, Germany).
Results
Analysis of Peptide-25 recognition by reconstituted TCR-ab pairs
To investigate the functional TCR able to bind a Peptide-25/ MHC complex at the clonal level, we first determined the usage of TCR-a and -b chains of Peptide-25-reactive Vb11 http://intimm.oxfordjournals.org/ b-chain were subcloned into a retrovirus vector and then transfected by retrovirus-mediated gene transfer into a TCR-aband CD4-deficient recipient T cell hybridoma cell line, TG40 (28) , and the reconstruction and functional specificity of the TCR was assessed by measuring IL-2 production (Fig. 1) . TG40-BP1 produced substantial amounts of IL-2 in response to Peptide-25 plus APC in a dose dependent manner. Enforced expression of CD4 molecules on TG40-BP1 (TG40-BP1/CD4) augmented IL-2 production even upon a lower dose of Peptide-25 stimulation (0.3 lg/ml). TG40-BP1/CD4 produced much more IL-2 than TG40-BP1 when stimulated with higher concentrations of Peptide-25 (10 lg/ml) (Fig. 1A) . TG40 transfectants of TCR-a alone or TCR-b alone did not respond to Peptide-25 in the presence of splenic APC (data not shown). These results indicate that recombinant TCR a-and b-chains can reconstruct functional TCR and recognize Peptide-25/I-A b complex to become IL-2-producing cells.
The specificity of BP1 TCR for Peptide-25 and splenic APC from C57BL/6 mice was examined by culturing TG40-BP1/CD4 with various I-A b -binding peptides in the presence of APC from different strains of mice. Although we do not show data here, among the various peptides only Peptide-25 could induce IL-2 production by TG40-BP1/CD4 in the presence of splenic APC from C57BL/6 (I-A b ) mice. The 11-mer from Peptide-25 was stimulatory while the 8-mer from Peptide-25 was ineffective. We then stimulated TG40-BP1/CD4 cells with a mutant of Peptide-25 as an altered peptide ligand (APL). The APL preserves those amino acid residues within Peptide-25 essential for I-A b binding, while one of TCR-binding amino acid residues, glutamic acid at position 248 of Peptide-25, was substituted to alanine, G248A. The APL stimulation at 10 lg/ml of TG40-BP1/CD4 induced marginal IL-2 production, and the stimulatory activity was much lower than with Peptide-25 (Fig. 1B) .
We then determined the amino acid sequences for the TCRa and -b chains of four other Peptide-25-reactive Th1 clones (BP4, BM5, BM7 and BM12). All these Th1 clones responded to Peptide-25 for proliferation and IFN-c production (23) . Analysis of the TCR-a and -b chain amino acid sequences for each clone revealed no obvious differences from BP1 except in the sequence and in the length of CDR3 regions of TCR a-and b-chain (Supplementary table 1 , available at International Immunology Online). Taking all these results together, the TCR-a5 and -b11 can reconstitute a functional TCR complex that is able to recognize and respond to Peptide-25 when presented in the context of I-A b . As BP1 is the best Peptide-25-reactive Th1 clone with respect to IFN-c production in response to Peptide-25, we chose BP1 TCR cDNAs for generating P25 TCR-Tg mice.
Generation of Peptide-25-reactive TCR-Tg mice
We then analyzed the clonal basis of preferential Th1 development by single TCR-Tg mice line expressing TCR-a5 and -b11. We constructed transgenes for TCR a5-and b11-chains under the control of the H-2K b promoter, the poly(A) signal from human b-globin gene and the immunoglobulin heavy chain enhancer. The transgenes were excised from the vector sequences and co-microinjected into fertilized eggs from C57BL/6 mice. Transgenic mice were screened by Southern blot analysis of tail DNA and by staining peripheral blood T cells with anti-Vb11, followed by FACS analysis. We obtained founder mice expressing FACS analysis revealed that >85% of splenic CD4 + T cells from the P25 TCR-Tg mice expressed TCR b11-chain, while 5-7% of splenic CD4 + T cells were Vb11 + in WT mice (22) . Over 98% of splenic CD4 + Tcells from the RAG-2 deficient P25 TCR-Tg mice expressed TCR Vb11-chain. Similar results were obtained by staining splenic CD4 + T cells from P25 TCR-Tg mice with anti-idiotypic antibody (KN7) for the recombinant TCR ab (A.K. and K.T., unpublished observation). We did not observe any significant KN7 + lymph node cells from transgenic mice expressing TCR a-chain alone or b-chain alone. We compared the expression patterns of LFA-1, CD25, CD28, CD44, CD45RB and CD69 on splenic CD4 + T cells from P25 TCR-Tg mice with those from WT mice. There were no significant differences in the expression pattern or mean fluorescence intensity of these cell surface molecules between the two groups. RT-PCR analysis revealed that T-bet and IFN-c mRNA expressions were not detected in freshly prepared splenic CD4 + cells of P25 TCR-Tg mice. Taking these results together, CD4 + T cells from P25 TCR-Tg mice are not pre-activated in vivo.
Naive CD4
+ T cells from P25 TCR-Tg mice are able to differentiate into both Th1 and Th2
Naive CD4 + T cells from P25 TCR-Tg and WT mice were purified from the spleen and stimulated in vitro with anti-CD3 in the presence of exhaustively T-and NK cell-depleted irradiated C57BL/6 splenocytes as APC. After 6 days in culture, the proliferated cells were harvested and re-stimulated for another day with anti-CD3 in the presence of APC. After culturing, IFN-c-and IL-4-producing cells were analyzed by intracellular staining. The cultured supernatants were subjected to ELISA assay for cytokine titration. The results revealed that in vitro stimulation of naive CD4 + T cells from P25 TCR-Tg mice with anti-CD3 induced the propagation of both IFN-c-and IL-4-producing cells to a similar extent as from WT mice (Fig. 2A) . The IFN-c and IL-4 production were confirmed by ELISA (Fig. 2B) . It is also evident from Fig. 2 that P25 TCR-Tg T cells has a higher proportion of IFN-c-producing cells and IFN-c production upon anti-CD3 stimulation compared with T cells from WT mice. These results indicate that naive CD4 + T cells from P25 TCR-Tg mice can differentiate into both Th1 and Th2 upon TCR cross-linking.
Induction of naive CD4 + T cells from P25 TCR-Tg mice to Th1 differentiation upon Peptide-25 stimulation
To examine the differentiation of naive CD4 + T cells from P25 TCR-Tg mice upon in vitro Peptide-25 stimulation, naive CD4 + splenic T cells were purified from P25 TCR-Tg mice and stimulated in vitro for 6 days with Peptide-25 in the presence of T and NK cell-depleted irradiated C57BL/6 splenocytes as APC. The activated cells produced IL-2 and proliferated upon Peptide-25 stimulation in a dose dependent manner in the presence of APC, but they did not produce IL-2 in the absence of Peptide-25 or in the presence of APC from strains of mice other than C57BL/6 mice (data not shown).
In another set of cultures, we stimulated naive CD4 + T cells from P25 TCR-Tg mice in vitro with Peptide-25. After 6 days in culture, the proliferated cells were re-stimulated for another day with immobilized anti-CD3. After culturing, IFN-c-and IL-4-producing cells were analyzed by cytoplasmic staining, followed by FACS analysis. The cultured supernatants were subjected to ELISA for titration of cytokine levels. As a control, we also cultured the cells with APL or medium alone. Naive CD4 + T cells stimulated with Peptide-25 in the presence of splenic APC became solely IFN-c-producing cells under neutral conditions (Fig. 3A) . IFN-c production was detected on the first day of culture and increased for the rest of the culture period at day 5 (data not shown). IL-4 secretion was not detected even after 5 days of culture. Importantly, stimulation of the cells with APL, in place of Peptide-25, solely induced IL-4-producing cells (Fig. 3B) . When we cultured naive CD4 We determined usage of TCR a-chain in five different Peptide-25-reactive Vb11 + Th1 clones. All Peptide-25-reactive Vb11 + Th1 clones expressed Va5, while each clone showed slightly different amino acid sequences in CDR3 regions of both Va5 and Vb11 chains (Supplementary table 1) . Although each Th1 clone responds to Peptide-25 to a similar extent with regard to proliferation and IFN-c production, it responds differently to a mutant of Peptide-25 where an amino acid required for TCR-binding had been substituted to alanine (data not shown). However, this may be due to the heterogeneity of the CDR3 regions of both Va5 and Vb11 chain. TG40 transfectants (TG40-BP1) expressing a and b chains from the BP1 clone constructed functional TCRs that recognize Peptide-25 in the context of I-A b on APC resulting in IL-2 production even in the absence of CD4 expression (Fig.  1A) . Enforced expression of CD4 in TG40-BP1 enhanced IL-2 production along with a low dose of Peptide-25 stimulation (Fig. 1B) , suggesting that the avidity of the TCR and Peptide-25/I-A b complex is potent enough to trigger TG40-BP1 transfectants. CD4 expression may facilitate the interaction between TG40-BP1 and APC, resulting in augmented IL-2 production. Intriguingly, the APL could stimulate TG40-BP1/ CD4 IL-2 production to a much lesser extent even at higher peptide concentrations (Fig. 1B) . As APL fully preserves the I-A b -binding amino acids of Peptide-25, the APL/I-A b complex may have lower avidity for the TCR compared with Peptide-25.
Expression profiles of cell surface activation markers on splenic T cells from P25 TCR-Tg mice were similar to these from WT mice, and mRNA expression of neither T-bet nor IFN-c was observed, suggesting that CD4 + T cells in P25 TCR-Tg mice are not pre-activated. Naive CD4 + T cells from P25 TCRTg mice could differentiate into IFN-c-and IL-4-producing cells upon anti-CD3 stimulation (Fig. 2) , indicating that they keep their potential to differentiate into either Th1-or Th2-lineage cells upon TCR ligation. Interestingly, naive CD4 + T cells differentiated solely to IFN-c-producing cells, but not to IL-4-producing cells upon Peptide-25 stimulation (Fig. 3) . This preferential Th1 differentiation induced by Peptide-25 stimulation was also dependent on APC from C57BL/6 mice. As we described, stimulation of naive CD4 + T cells from P25 TCR-Tg mice with Peptide-25 at 10 lg/ml (6.0 lM) preferentially induces Th1 development. In contrast, when we stimulated the T cells with Peptide-25 at 0.1 lg/ml (0.06 lM), we observed a Th2-dominant response (data not shown). These observations are consistent with the published data (31) addressing that IFN-c production is preferentially induced at 1.6-6.2 lM of OVA peptide in the OVA TCR-Tg mouse model. These results further support the notion that the Peptide-25 has an intrinsically highly potential to induce Th1. Intriguingly, stimulation with APL in place of Peptide-25 induced solely IL-4-producing cells (Fig. 3) . When we analyzed APC cell surface marker expression after stimulation with either Peptide-25 or APL, we did not observe an activation-dependent alteration of cell surface marker expression such as CD80, CD86, or CD40 (data not shown). The differences between Peptide-25 and APL regarding Th1 and Th2 differentiation may be due to differences in avidity between Peptide-25/I-A b and APL/I-A b to TCR. Differentiation of naive CD4 + Th precursors to Th1 and Th2 is affected by the manner and environment that they encounter (2, 32, 33) . The strength of interaction between the TCR and MHC/peptide complex affects the lineage commitment of Th cells (15, 17, 31, 34) . It is well known that Th1 cell development involves IFN-c signaling through STAT1 and IL-12 signaling through STAT4 activation (35, 36) . Peptide-25-induced Th1 differentiation of naive CD4 + Tcells from P25 TCR-Tg mice was observed even in the presence of anti-IFN-c and anti-IL-12 (Fig. 4) . We obtained similar results using T cells of STAT1 deficient P25 TCR-Tg mice ( (Fig. 6) . As Chinese hamster ovary cells do not express detectable levels of CD80, CD86, ICAM-1, OX40L or B7h, we are in favor of the hypothesis that preferential induction of Th1 development in P25 TCR-Tg naive CD4 + T cells may be independent of these well-known co-stimulating signals from APC. A complex network of gene transcription events is likely to be involved in establishing an environment that promotes Th1 development. T-bet, a recently discovered member of T-box transcription factor is expressed selectively in thymocytes and Th1 cells, and controls the expression of the hallmark Th1 cytokine, IFN-c (47). T-bet expression correlates with IFN-c expression in Th1 and NK cells. Ectopic expression of T-bet both transactivates the IFN-c gene and induces endogenous IFN-c production (47) . T-bet appears to initiate Th1 lineage development from naive Th cells both by activating Th1 genetic programs and by repressing the opposing Th2 programs (47) . It has been reported that T-bet is regulated by IFN-c signaling through STAT1 activation in the context of TCR ligation (10, 11) and induces chromatin remodeling of the ifn-c locus (48) . As naive CD4 + T cells are capable of differentiating into IFN-c producing cells even in the presence of anti-IFN-c, the interaction between Peptide-25/I-A b and TCR may directly induce T-bet that leads to Th1 differentiation. We are currently investigating T-bet expression during Th1 differentiation in P25 TCR-Tg naive CD4 + T cells in response to Peptide-25-loaded I-A b -CHO. There are several possibilities to account for the immunogenicity and adjuvant activity of Peptide-25 for Th1 development. First, Peptide-25 may activate DCs directly or indirectly through Th cells to enhance expression of co-stimulatory molecules leading to activate Th1 precursors by enhancing well-known transcription factors such as T-bet or unidentified 'master cytokine' for Th1 development. Second, the avidity of Peptide-25 to its specific TCR would be potent enough leading to Th1 development preferentially. Third, Peptide-25 might enhance activation or selection of unidentified T cell subpopulations that suppress GATA-3 leading to Th2 development.
In conclusion, we have presented data showing that naive CD4 + T cells from P25 TCR-Tg mice stimulated with Peptide-25/I-A b that polarize to Th1 differentiation preferentially in the absence of IFN-c or IL-12. We propose the hypothesis that direct interaction of the specific antigenic peptide/MHC class II complex and TCR may primarily influence the determination of naive CD4 + T cell fate in development towards the Th1 subset. Therefore, P25 TCR-Tg mice may provide us with new insights and help us understand how Th cell fate is determined.
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